US-based Biohaven Pharmaceutical is set to initiate a Phase II/III clinical trial of its product candidate trigriluzole for the treatment of patients with obsessive-compulsive disorder (OCD).

The firm has received approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to start clinical investigations of the candidate for OCD.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Being a substrate for the gut transporters (PepT1), trigriluzole is a glutamate modulator designed to improve bioavailability.

The product candidate is developed as a once-daily dose to ensure compliance and long-term outcomes.

Biohaven Pharmaceutical CEO Vlad Coric said: “OCD is a serious neuropsychiatric disorder for which many patients do not have effective or tolerable therapy, and in which glutamate dysregulation may play a significant role.

“OCD is a serious neuropsychiatric disorder many patients do not have effective or tolerable therapy.”

“We are very pleased to explore the potential of trigriluzole as a safe and effective therapy for these patients as part of our mission to develop best-in-class and first-in-class therapies for patients with severe neurologic and neuropsychiatric diseases.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In previous clinical trials, trigriluzole is reported to have demonstrated favourable safety and tolerability profile, and the dosing regimen in Phase II/III trial is based on recent clinical findings of the candidate.

Trigriluzole is being further studied in a long-term, 48-week extension study for patients with SCA.

Apart from trigriluzole, the firm is evaluating another investigational drug rimegepant in a Phase III clinical trial for the treatment of migraine with top-line results scheduled to be available in the first quarter of next year.

Additionally, Biohaven intends to initiate a bioequivalence study for BHV-0223 by the end of this year in amyotrophic lateral sclerosis (ALS) patients.